The calcium-sensitive Sigma-1 receptor prevents cannabinoids from provoking glutamate NMDA receptor hypofunction: implications in antinociception and psychotic diseases
- PMID:24485144
- DOI: 10.1017/S1461145714000029
The calcium-sensitive Sigma-1 receptor prevents cannabinoids from provoking glutamate NMDA receptor hypofunction: implications in antinociception and psychotic diseases
Abstract
Through the cannabinoid receptor 1 (CB1), the endocannabinoid system plays a physiological role in maintaining the activity of glutamate N-methyl-D-aspartate (NMDA) receptor within harmless limits. The influence of cannabinoids must be proportional to the stimulus in order to prevent NMDAR overactivation or exaggerated hypofunction that may precipitate symptoms of psychosis. In this framework, the recently reported association of CB1s with NMDARs, which mediates the reduction of cannabinoid analgesia promoted by NMDAR antagonism, could also support the precipitation of schizophrenia brought about by the abuse of smoked cannabis, mostly among vulnerable individuals. Accordingly, we have investigated this possibility using neuroprotection and analgesia as reporters of the CB1-NMDAR connection. We found that the Sigma 1 receptor (σ1R) acts as a safety switch, releasing NMDARs from the influence of CB1s and thereby avoiding glutamate hypofunction. In σ1R(-/-) mice the activity of NMDARs increases and cannot be regulated by cannabinoids, and NMDAR antagonism produces no effect on cannabinoid analgesia. In wild-type mice, ligands of the σ1R did not affect the CB1-NMDAR regulatory association, however, experimental NMDAR hypofunction enabled σ1R antagonists to release NMDARs from the negative control of CB1s. Of the σ1R antagonists tested, their order of activity was: S1RA > BD1047 ≫ NE100 = BD1063, although SKF10047, PRE-084 and (+)pentazocine were inactive yet able to abolish the effect of S1RA in this paradigm. Thus, the σ1R controls the extent of CB1-NMDAR interaction and its failure might constitute a vulnerability factor for cannabis abuse, potentially precipitating schizophrenia that might otherwise be induced later in time by the endogenous system.
Comment in
- Why sigma-1 receptor dysfunction might confer vulnerability to cannabis-induced psychosis.Arnold JC.Arnold JC.Int J Neuropsychopharmacol. 2014 Dec;17(12):1911-3. doi: 10.1017/S1461145714000960. Epub 2014 Aug 13.Int J Neuropsychopharmacol. 2014.PMID:25116043No abstract available.
Similar articles
- The ON:OFF switch, σ1R-HINT1 protein, controls GPCR-NMDA receptor cross-regulation: implications in neurological disorders.Rodríguez-Muñoz M, Cortés-Montero E, Pozo-Rodrigálvarez A, Sánchez-Blázquez P, Garzón-Niño J.Rodríguez-Muñoz M, et al.Oncotarget. 2015 Nov 3;6(34):35458-77. doi: 10.18632/oncotarget.6064.Oncotarget. 2015.PMID:26461475Free PMC article.
- The σ1 receptor engages the redox-regulated HINT1 protein to bring opioid analgesia under NMDA receptor negative control.Rodríguez-Muñoz M, Sánchez-Blázquez P, Herrero-Labrador R, Martínez-Murillo R, Merlos M, Vela JM, Garzón J.Rodríguez-Muñoz M, et al.Antioxid Redox Signal. 2015 Apr 1;22(10):799-818. doi: 10.1089/ars.2014.5993. Epub 2015 Feb 18.Antioxid Redox Signal. 2015.PMID:25557043Free PMC article.
- Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor.Rodríguez-Muñoz M, Onetti Y, Cortés-Montero E, Garzón J, Sánchez-Blázquez P.Rodríguez-Muñoz M, et al.Mol Brain. 2018 Sep 17;11(1):51. doi: 10.1186/s13041-018-0395-2.Mol Brain. 2018.PMID:30223868Free PMC article.
- The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia.Sánchez-Blázquez P, Rodríguez-Muñoz M, Garzón J.Sánchez-Blázquez P, et al.Front Pharmacol. 2014 Jan 2;4:169. doi: 10.3389/fphar.2013.00169.Front Pharmacol. 2014.PMID:24427139Free PMC article.Review.
- Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction.Rodríguez-Muñoz M, Sánchez-Blázquez P, Merlos M, Garzón-Niño J.Rodríguez-Muñoz M, et al.Oncotarget. 2016 Aug 23;7(34):55840-55862. doi: 10.18632/oncotarget.10095.Oncotarget. 2016.PMID:27323834Free PMC article.Review.
Cited by
- The ON:OFF switch, σ1R-HINT1 protein, controls GPCR-NMDA receptor cross-regulation: implications in neurological disorders.Rodríguez-Muñoz M, Cortés-Montero E, Pozo-Rodrigálvarez A, Sánchez-Blázquez P, Garzón-Niño J.Rodríguez-Muñoz M, et al.Oncotarget. 2015 Nov 3;6(34):35458-77. doi: 10.18632/oncotarget.6064.Oncotarget. 2015.PMID:26461475Free PMC article.
- Sigma 1 Receptor Antagonists Inhibit Manic-Like Behaviors in Two Congenital Strains of Mice.Sánchez-Blázquez P, Cortés-Montero E, Rodríguez-Muñoz M, Garzón J.Sánchez-Blázquez P, et al.Int J Neuropsychopharmacol. 2018 Oct 1;21(10):938-948. doi: 10.1093/ijnp/pyy049.Int J Neuropsychopharmacol. 2018.PMID:29860313Free PMC article.
- The ALS-related σ1R E102Q Mutant Eludes Ligand Control and Exhibits Anomalous Response to Calcium.Rodríguez-Muñoz M, Cortés-Montero E, Garzón-Niño J, Sánchez-Blázquez P.Rodríguez-Muñoz M, et al.Int J Mol Sci. 2020 Oct 4;21(19):7339. doi: 10.3390/ijms21197339.Int J Mol Sci. 2020.PMID:33020464Free PMC article.
- Critical role of sigma-1 receptors in central neuropathic pain-related behaviours after mild spinal cord injury in mice.Castany S, Gris G, Vela JM, Verdú E, Boadas-Vaello P.Castany S, et al.Sci Rep. 2018 Mar 1;8(1):3873. doi: 10.1038/s41598-018-22217-9.Sci Rep. 2018.PMID:29497125Free PMC article.
- The Sigma-1 Receptor as a Pluripotent Modulator in Living Systems.Su TP, Su TC, Nakamura Y, Tsai SY.Su TP, et al.Trends Pharmacol Sci. 2016 Apr;37(4):262-278. doi: 10.1016/j.tips.2016.01.003. Epub 2016 Feb 9.Trends Pharmacol Sci. 2016.PMID:26869505Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases